Tierney Baum
PersonHeard in 2 episodes across 1 show since Oct 2026
Tierney Baum is a life-sciences journalist and editor covering biotechnology and pharmaceutical development.
Episodes
First heard
Guest appearances
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 1 |
| Nov 2026 | 1 |
Email alert
Email me when Tierney Baum comes up on a podcast
One email a week at most, with the new episodes that mention Tierney Baum. Free, no account needed, unsubscribe in one click.
What Tierney Baum has said on podcasts
9 statements
Merck and Moderna’s personalized neoantigen vaccine modality met a late-stage trial objective.
“this modality could meet in a late stage trial.”
Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton OddsListen at 9:45
The neoantigen vaccine field likely needs several years for solid answers.
“we're probably still a ways out a couple years out from beginning to really get more solid answers to some of these questions”
Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton OddsListen at 11:58
Moderna and Merck’s neoantigen program leads the pipeline with the most Phase 3 trials.
“they're still clearly ahead in the pipeline. They have the most phase three trials.”
Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton OddsListen at 12:23
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
2 episodes featuring Tierney Baum, newest first